We claim:

1. Crystalline Form I of Ezetimibe.

2. The crystalline form of claim 1, having an X-ray powder diffraction pattern with Cu $K_{\alpha 1}$ radiation comprising peaks at about 13.8 ± 0.1, 15.8 ± 0.1, 24.5 ± 0.1, and 26.3 ± 0.1 degrees 2θ.

3. The crystalline form of claim 2, further comprising peaks at about 7.9 ± 0.1, 22.9 ± 0.1, and 23.4 ± 0.1 degrees 2θ.

4. The crystalline form of claim 1, having an X-ray powder diffraction pattern substantially as shown in Figure 1.

5. The crystalline form of claim 1, having an infrared absorption spectrum comprising a broad peak at about 3270 cm^{-1}.

6. The crystalline form of claim 1, having an infrared absorption spectrum substantially as shown in Figure 2.

7. The crystalline form of claim 1, having endothermic absorption peak at about 163 °C by differential scanning calorimetry.

8. The crystalline form of claim 1, having a differential scanning calorimetry curve substantially as shown in Figure 5.

9. A process for preparing crystalline Form I of ezetimibe, comprising

   a. reacting 3-{2-[3-(fluorophenyl)-3-(trimethyl silyloxy)-propyl]-3-(4-fluoro phenyl amino)-3-(4-trimethyl silyloxyl phenyl)-1-oxo-propyl}-4-(S)-phenyl oxazolidin-2-one with bistrimethyl silyl acetamide;

   b. quenching the reaction solution of step (a);

   c. adding sulfuric acid in an alcoholic solvent to the quenched reaction solution; and

   d. isolating solid Form I of Ezetimibe.

10. Crystalline Form I of Ezetimibe, prepared according to the process of claim 9.

11. A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the crystalline form of claim 1 and one or more pharmaceutically acceptable excipients.

12. A compound of Ezetimibe, which comprises crystalline Form II.

13. The compound of claim 12, wherein said crystalline Form II has an X-ray diffraction pattern with Cu $K_{\alpha 1}$ radiation comprising peaks at about 8.2 ± 0.1, 16.4 ± 0.1, 20.2 ± 0.1, and 29.7 ± 0.1 degrees 2θ.

14. The compound of claim 13, wherein said peaks further comprise 13.6 ± 0.1 degrees 2θ.

15. The compound of claim 12, wherein said crystalline Form II has an IR spectrum comprising consecutive peaks at about 3438 and about 3272 cm^{-1}.

16. The compound of claim 12, wherein said crystalline Form II has a DSC spectrum having an endothermic peak at about 164 °C.

17. The compound of claim 12, wherein said Ezetimibe has an X-ray diffraction pattern substantially same as Figure 6.

18. The compound of claim 12, wherein said Ezetimibe has an IR spectrum substantially same as Figure 7.

19. A process for preparing crystalline Form II of Ezetimibe comprising

a. providing pressure to crystalline Form I of Ezetimibe.

20. The process of claim 19, wherein said pressure is between about 4-7 tonnes/cm^2.

21. The process of claim 19, wherein said pressure is between about 5-6 tonnes/cm^2.

22. The process of claim 19, wherein said pressure is provided for about 1-120 seconds.

23. The process of claim 19, wherein said pressure is provided for about 30-60 seconds.

24. A compound of Ezetimibe, which is prepared according to the process of claim 19.

25. A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the compound of claim 12 and one or more pharmaceutically acceptable excipients.

26. A compound of Ezetimibe, which comprises crystalline Form I and crystalline Form II of Ezetimibe.

27. An amorphous form of Ezetimibe.

28. The amorphous form of claim 27, having an X-ray diffraction pattern substantially same as Figure 11.

29. The compound of claim 27, having an IR spectrum substantially same as Figure 12.

30. A pharmaceutical composition comprising a prophylactically or therapeutically effective amount of the amorphous form of claim 27 and one or more pharmaceutically acceptable excipients.

31. A method of treating or preventing a high cholesterol problem comprising administering a patient in need of such treatment or prevention with a prophylactically or therapeutically effective amount of Ezetimibe comprising crystalline Form I of Ezetimibe.

32. A method of treating or preventing a high cholesterol problem comprising administering a patient in need of such treatment or prevention with a prophylactically or therapeutically effective amount of Ezetimibe comprising crystalline Form II of Ezetimibe.

33. A method of treating or preventing a high cholesterol problem comprising administering a patient in need of such treatment or prevention with a prophylactically or therapeutically effective amount of Ezetimibe comprising an amorphous form of Ezetimibe.